Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model
Background Development of novel immunotherapeutics in oncology is of major interest. Their preclinical evaluation relies on two key elements: the relevance of the animal model used and the implementation of a comprehensive strategy to deeply characterize the mechanisms underlying drug resistance or sensitivity. Methods Using a syngeneic sarcoma mouse model treated with anti-PD-L1, we investigated […]
“GPCR-ome” modulation upon PD1 / PDL1 axis blockade
Background Immunotherapy represents a novel weapon in the cancer armamentarium, with unprecedented responses observed in several indications, including metastatic melanoma and lung cancer. However, the limited response rate, accounting for approximately 30%, requires further optimization and calls for a better understanding of the mechanisms underlying sensitivity to immune checkpoint inhibitors. G protein-coupled receptors (GPCRs) are […]
Why IDO1 blockade lowered kynurenine but failed to improve anti-PDL1 efficacy in sarcoma
The Kynurenine Pathway as a possible resistance mechanism to immunotherapy in sarcomas
Background Sarcomas are heterogeneous malignant mesenchymal tumors known to be particularly resistant to immunotherapy. This resistance highlights the need to better understand the biological mechanisms limiting response to immune checkpoint inhibitors. We previously observed increased activity of the kynurenine pathway in the plasma of patients treated with pembrolizumab and metronomic cyclophosphamide. The kynurenine pathway is […]
Why melanoma escapes BRAF inhibitors — the AhR transcription factor behind resistance and relapse
